Sino Medical Sciences Technology In (688108) - Total Liabilities
Based on the latest financial reports, Sino Medical Sciences Technology In (688108) has total liabilities worth CN¥285.74 Million CNY (≈ $41.81 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Sino Medical Sciences Technology In liquidity resilience to evaluate the company's liquid asset resilience ratio.
Sino Medical Sciences Technology In - Total Liabilities Trend (2016–2025)
This chart illustrates how Sino Medical Sciences Technology In's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Sino Medical Sciences Technology In.
Sino Medical Sciences Technology In Competitors by Total Liabilities
The table below lists competitors of Sino Medical Sciences Technology In ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Garcia Reguera S.A.
BA:REGE
|
Argentina | AR$4.61 Billion |
|
MORIMATSU INT.H.C. (HK)
F:1S5
|
Germany | €4.27 Billion |
|
Jiangyin Electrical Alloy Co Ltd
SHE:300697
|
China | CN¥1.34 Billion |
|
Azorim Investment Development and Construction Co Ltd
TA:AZRM
|
Israel | ILA6.66 Billion |
|
Chengdu Spaceon Electronics Co Ltd Class A
SHE:002935
|
China | CN¥1.10 Billion |
|
Superloop Ltd
AU:SLC
|
Australia | AU$241.95 Million |
|
Shenyang Toly Bread Co Ltd
SHG:603866
|
China | CN¥2.04 Billion |
|
Mission Produce Inc
NASDAQ:AVO
|
USA | $396.60 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Sino Medical Sciences Technology In's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Sino Medical Sciences Technology In balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sino Medical Sciences Technology In's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sino Medical Sciences Technology In (2016–2025)
The table below shows the annual total liabilities of Sino Medical Sciences Technology In from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥-931.81 Million ≈ $-136.35 Million |
-331.67% |
| 2024-12-31 | CN¥402.22 Million ≈ $58.86 Million |
+24.08% |
| 2023-12-31 | CN¥324.17 Million ≈ $47.44 Million |
+79.96% |
| 2022-12-31 | CN¥180.13 Million ≈ $26.36 Million |
+14.06% |
| 2021-12-31 | CN¥157.92 Million ≈ $23.11 Million |
+13.10% |
| 2020-12-31 | CN¥139.63 Million ≈ $20.43 Million |
+30.36% |
| 2019-12-31 | CN¥107.11 Million ≈ $15.67 Million |
+2.18% |
| 2018-12-31 | CN¥104.83 Million ≈ $15.34 Million |
+1.16% |
| 2017-12-31 | CN¥103.62 Million ≈ $15.16 Million |
+32.74% |
| 2016-12-31 | CN¥78.06 Million ≈ $11.42 Million |
-- |
About Sino Medical Sciences Technology In
Sino Medical Sciences Technology Inc., a medical device company, engages in the research, development, production, and distribution of interventional medical devices in China. Its products include coronary drug stents, coronary balloons catheter, intracranial rapid exchange balloons, and intracranial drug-eluting stents, as well as transapical mitral valve replacement system. Sino Medical Science… Read more